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Abstract
Background: Risk stratification models can be employed at the emergency department (ED) to evaluate patient
prognosis and guide choice of treatment. We derived and validated a new cardiovascular risk stratification model
comprising vital signs, heart rate variability (HRV) parameters, and demographic and electrocardiogram (ECG) variables.
Methods: We conducted a single-center, observational cohort study of patients presenting to the ED with chest pain.
All patients above 21 years of age and in sinus rhythm were eligible. ECGs were collected and evaluated for 12-lead
ECG abnormalities. Routine monitoring ECG data were processed to obtain HRV parameters. Vital signs and
demographic data were obtained from electronic medical records. Thirty-day major adverse cardiac events (MACE)
were the primary endpoint, including death, acute myocardial infarction, and revascularization. Candidate variables
were identified using univariate analysis; the model for the final risk score was derived by multivariable logistic
regression. We compared the performance of the new model with that of the thrombolysis in myocardial infarct (TIMI)
score using receiver operating characteristic (ROC) analysis.
Results: In total, 763 patients were included in this study; 254 (33 %) met the primary endpoint, the mean age was 60
(σ = 13) years, and the majority was male (65 %). Nineteen candidate predictors were entered into the multivariable
model for backward variable elimination. The final model contained 10 clinical variables, including age, gender, heart
rate, three HRV parameters (average R-to-R interval (RR), triangular interpolation of normal-to-normal (NN) intervals, and
high-frequency power), and four 12-lead ECG variables (ST elevation, ST depression, Q wave, and QT prolongation). Our
proposed model outperformed the TIMI score for prediction of MACE (area under the ROC curve 0.780 versus 0.653). At
the cutoff score of 9 (range 0–37), our model had sensitivity of 0.709 (95 % CI 0.653, 0.765), specificity of 0.674 (95 % CI
0.633, 0.715), positive predictive value of 0.520 (95 % CI 0.468, 0.573), and negative predictive value of 0.823 (95 % CI 0.
786, 0.859).
Conclusions: A non-invasive and objective ECG- and HRV-based risk stratification tool performed well against the TIMI
score, but future research warrants use of an external validation cohort.
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Background
Chest pain is the most frequent complaint in patients
over 45 years of age presenting to the emergency depart-
ment (ED) in the USA [1]. The first priority in the evalu-
ation of patients with chest pain is risk stratification to
differentiate those who are in acute cardiovascular dis-
tress from those who are not. Risk stratification allows
for an appropriate therapeutic strategy and an effective
allocation of ED resources.
The American College of Cardiology/American Heart
Association (ACC/AHA) practice guidelines recommend
the use of validated risk scoring models such as the
thrombolysis in myocardial infarction (TIMI), platelet
glycoprotein IIb/IIIa in unstable angina: receptor sup-
pression using integrilin (PURSUIT), and global registry
of acute coronary events (GRACE) for cardiovascular
risk stratification [2–6]. However, commonly employed
cardiovascular risk models rely on traditional clinical in-
dicators that are subjective, susceptible to risk factor
modification (e.g., anticholesterol or antihypertensive
therapy), may not be immediately available, and often do
not correlate well with long-term or short-term out-
comes [7–10]. Consequently, there is a need for a quan-
titative and rapid method to guide patient disposition in
the ED.
Heart rate variability (HRV) parameters are quantita-
tive measures of the interval between adjacent QRS
complexes, mathematically derived from the electrocar-
diogram (ECG) [11–13]. Beat-to-beat interval fluctua-
tions principally represent the short-term cardiovascular
control exercised by the autonomic nervous system [14].
There is an increasing recognition of HRV parameters as
powerful independent predictors of many cardiovascular
pathological conditions [15–24], and their potential role
in early cardiovascular risk stratification [25, 26].
This study aims to develop a novel risk stratification
model composed of HRV parameters, demographic data,
traditional vital signs and 12-lead ECG variables for the
prediction of major adverse cardiac events (MACE) in
patients with chest pain (henceforth referred to as the
Singapore General Hospital Emergency Department risk
stratification model (SEDRSM)). This study hypothesizes
that the SEDRSM will perform better than an estab-
lished risk stratification tool (TIMI) at predicting MACE




We conducted a prospective, non-randomized, observa-
tional study of patients presenting to the ED with chest
pain from March 2010 until August 2015. This study
was performed at the ED of the Singapore General Hos-
pital (SGH), a tertiary care hospital in Singapore. ED triage
is performed by nurses using the national Singaporean
patient acuity category scale (PACS), a symptom-based tri-
age system without strict physiological criteria. ED pa-
tients are classified with a PACS score, which ranges from
1 to 4 and represents the degree of urgency in patient
attendance. Patients with PACS 1 are the most critically
ill, those with PACS 2 are non-ambulant, those with
PACS 3 are ambulant, and those with PACS 4 are
non-emergencies. Our study focuses on patients present-
ing with chest pain, who routinely receive a 12-lead ECG
investigation (Philips PageWriter TC50 Cardiograph) dur-
ing triage and are placed in PACS 1 or 2 units where they
receive further ECG monitoring (ZOLL X Series Monitor
defibrillator). The study was approved by the local ethics
committee (SingHealth Centralised Institutional Review
Board, Singapore) with a waiver of patient consent.
Patient recruitment and eligibility
All patients older than 21 years of age with a primary
complaint of non-traumatic chest pain were eligible. Pa-
tients presenting in non-sinus rhythm (arrhythmias,
asystole, complete heart blocks, or pacemaker rhythms)
were excluded due to interference of these phenomena
with the interpretation of QRS complexes. Similarly, pa-
tients with a high percentage of artifacts, ectopic beats,
and non-sinus beats (>30 % of ECG recordings) were ex-
cluded due to their potential biasing effect on the HRV
calculations [27]. Finally, patients who were lost to fol-
low up or transferred to other (private) hospitals within
the 30-day time frame were excluded, on account of in-
ability to ascertain whether these patients had reached
our primary endpoint.
Data collection and processing
All data were collected on standardized forms in a Re-
search Electronic Data Capture (REDCap) database. The
electronic medical records (EMRs) were analyzed for
demographic characteristics, medical history, presenting
symptoms, clinical information, and laboratory results.
A trained research coordinator prospectively down-
loaded 12-lead ECG tracings from the ZOLL X Series
monitor defibrillator on a daily basis. We use our in-
house software package for ECG signal processing and
parameter calculation [28]. Noise was manually removed
from the lead II ECG tracing and its sample of 6 minutes
was stored in an Excel (Microsoft Office 2007; Micro-
soft, Redmond, WA, USA) file for further processing. A
5–28 Hz band-pass filter was applied to the lead II sam-
ple to facilitate peak detection [29]. QRS complexes
were detected using a threshold-plus-derivative method
that has been previously validated [28]. Time domain
and frequency domain HRV parameters were calculated
in accordance with the guidelines outlined by the Task-
force of the European Society of Cardiology [30].
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Vital signs were recorded at initial ED patient presen-
tation using the Propaq CS Vital Signs Monitor (Welch
Allyn, Skaneateles, NY, USA). The first set of complete
vital signs obtained at initial presentation was used for
this study. The 12-lead ECG tracings recorded during
triage were used for the evaluation of ECG variables.
These tracings were recorded using a Philips PageWriter
TC50 cardiograph and subsequently extracted for ana-
lysis and storage. A trained research associate, blinded
to patient outcomes, ascertained whether the patient
was in sinus rhythm, and evaluated the 12-lead ECG
tracings for abnormalities. We followed the definitions
of ECG variables as described in John Hampton’s book
“The ECG Made Easy”.
We tested the SEDRSM against the TIMI score for un-
stable angina (UA)/non-ST elevation myocardial infarc-
tion (NSTEMI), a score that has been employed on the
ED to predict MACE within 30 days of presentation to
the ED with chest pain [31]. Data pertaining to the TIMI
score criteria were retrieved from the EMRs and used to
construct the TIMI score.
Outcomes
The primary endpoint of this study, MACE, was a com-
posite outcome of death, acute myocardial infarction,
and revascularization, including coronary artery bypass
graft (CABG) or percutaneous coronary intervention
(PCI), within 30 days of presentation to the ED. Patients
were followed up and EMRs were reviewed to ascertain
whether the patient had experienced an endpoint criter-
ion within 30 days after presentation.
Statistical analysis
SPSS (version 21.0; SPSS Inc, Chicago, IL, USA) software
was used for statistical analysis. Derivation and valid-
ation of the SEDRSM was done in the same cohort. Uni-
variate relationships between baseline characteristics and
MACE were assessed using the appropriate statistical
test, based on type and distribution of data. We tested
normality of distribution by inspecting normality graphs
and interpreting the Kolmogorov-Smirnov quantitative
normality test.
A total of 16 HRV parameters, 13 ECG variables, 7 vital
signs, and 3 demographic variables (age, gender, and race)
were screened as candidate predictors of MACE using the
same univariate analytical method described previously.
Variables associated with a p value <0.05 were selected
and categorized in order to facilitate scoring and increase
applicability at the ED. HRV parameter category cutoffs
were chosen based on the visual comparison between
HRV parameter value and frequency of MACE occur-
rence. ECG variables were dichotomous. Vital signs and
demographics were categorized based on recognized
(physiological) cutoff values.
We introduced the categorized candidate variables
into an automated likelihood ratio backward stepwise lo-
gistic regression model. The retained candidate variables
were used to construct the SEDRSM. All unstandardized
coefficients were normalized by dividing them by the
smallest coefficient, and subsequently rounded off to the
nearest integer. The SEDRSM score was then calculated
by a simple arithmetic sum of the integers assigned to
the criteria satisfied.
The overall goodness of fit of the model was assessed
by the Hosmer-Lemeshow test. The predictive accuracy
of the SEDRSM and TIMI score was assessed using
the area under the receiver operating characteristic
(AUROC) curve. Discriminatory values (i.e., sensitiv-
ity, specificity, positive predictive value, and negative
predictive value) were also determined for both risk
stratification models.
Results
We included 763 patients in the study. The baseline
characteristics of our total patient cohort and of those
with and without a MACE (our primary endpoint) are
shown in Table 1. A total of 254 patients experienced a
MACE, versus a total of 509 who did not. The mean age
of our cohort was 60 (SD = 13) years. The majority of
the population was male (65 %). In the group that expe-
rienced a MACE, the patients were older (61.75 years)
(p = 0.001), there were more male patients (72.8 %, p =
0.001) and more patients with diabetes mellitus (44.5 %,
p = 0.001), and fewer patients with respiratory disease
(1.6 %, p = 0.012). We also found that patients who expe-
rienced a MACE were more frequently admitted, specif-
ically more often to general wards and intensive care
wards. No other significant differences were found be-
tween the groups who did or not experience. The risk
factors hypertension and hyperlipidemia were present in
over half the cohort. The frequencies of all different
types of MACE are shown in Table 2. The most frequent
MACE was revascularization (24.5 %) by either PCI, or
CABG, or both, followed closely by MI (23.6 %). Death
(2.0 %) was the least frequent MACE experienced by pa-
tients in this cohort.
Table 3 shows the univariate association between vital
signs, HRV parameters, 12-lead ECG variables, and our
endpoint. A total of 19 candidates for the SEDRSM, in-
cluding gender and age, were identified (p < 0.05). Heart
rate and diastolic blood pressure were found to be sig-
nificantly elevated in the cohort that experienced a
MACE within 30 days. The presence of five ECG vari-
ables was strongly associated with the occurrence of a
MACE within 30 days. Lastly, nine HRV parameters
were found to be significantly different in the cohort that
experienced a MACE versus the cohort that did not ex-
perience a MACE; these were average R-to-R interval
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(RR), SDRR (SD R-to-R interval), average HR, root mean
square of successive differences (RMSSD), the number
of interval differences of successive normal-to-normal
(NN) intervals greater than 50 ms (NN50), the propor-
tion derived by dividing NN50 by the total number of
NN intervals (pNN50), triangular interpolation of NN
interval histogram (TINN), very low frequency (VLF),
and high frequency (HF).
Table 2 Frequency of MACE types within 30 days
Event Number of patients (%)






Revascularization is a composite of percutaneous coronary intervention (PCI)
and coronary artery bypass graft (CABG). Patients may have had more than
one major adverse cardiac event (MACE). MI myocardial infarction
Table 3 Comparison of vital signs, ECG variables, and HRV parameters
in patients with and without MACE within 30 days of arrival at the ED
No MACE MACE P-value
(n = 509) (n = 254)
Vital signs, μ (σ)
Temperature 36.4 (0.8) 36.4 (0.7) 0.517
Heart rate 75 (22) 81 (23) 0.001*
Respiratory rate 18 (1) 18 (1) 0.791
Systolic BP 139 (33) 138 (41) 0.690
Diastolic BP 75 (18) 78 (21) 0.005*
SpO2 99 (3) 99 (3) 0.505
Pain score 2 (4) 2 (5) 0.090
ECG variables, no. (%)
ST elevation 13 (2.6) 52 (20.6) <0.001*
ST depression 13 (2.6) 53 (20.9) <0.001*
T inversion 82 (16.1) 69 (27.2) <0.001*
Q wave 17 (3.3) 35 (13.8) <0.001*
QT prolongation 159 (31.2) 102 (40.2) 0.015*
Left axis deviation 36 (7.1) 18 (7.1) 1.000
Right axis deviation 15 (2.9) 8 (3.1) 1.000
LBBB 3 (0.6) 2 (0.8) 1.000
RBBB 36 (7.1) 15 (5.9) 0.645
IVCD 3 (0.6) 11 (4.3) 0.001*
LAA 7 (1.4) 5 (2.0) 0.546
LVH 62 (12.2) 41 (16.1) 0.144
RVH 5 (1.0) 1 (0.4) 0.669
HRV parameters, μ (σ)
Average RR 0.824 (0.241) 0.770 (0.233) 0.001*
SD RR 0.035 (0.028) 0.029 (0.031) 0.010*
Average HR 73.13 (21.16) 78.11 (23.31) 0.001*
SD HR 3.27 (2.66) 2.99 (2.30) 0.135
RMSSD 0.028 (0.031) 0.021 (0.031) 0.001*
NN50 10.0 (26) 6.0 (21) 0.018*
pNN50 2.85 (8.42) 1.55 (7.59) 0.013*
Triangular index 2.97 (1.96) 2.87 (1.94) 0.640
TINN 0.130 (0.118) 0.102 (0.113) 0.002*
Total power 0.470 (0.140) 0.485 (0.155) 0.428
VLF power 0.217 (0.169) 0.246 (0.202) 0.030*
LF power 0.113 (0.102) 0.110 (0.083) 0.265
Normalized LF 50.56 (30.52) 52.99 (35.85) 0.463
HF 0.113 (0.110) 0.098 (0.110) 0.029*
Normalized HF 49.44 (30.52) 47.01 (35.85) 0.463
LF/HF ratio 1.02 (1.33) 1.13 (1.68) 0.428
Vital signs and heart rate variability (HRV) parameters are expressed as mean (μ)
and standard deviation (σ). MACE major adverse cardiac events, BP blood pressure,
ECG electrocardiograph, LBBB left bundle branch block, RBBB right bundle branch
block, IVCD intraventricular conduction defect, LAA left atrial abnormality, LVH left
ventricular hypertrophy, RVH right ventricular hypertrophy, HRV heart rate variability,
NN normal-to-normal, SD standard deviation, RMSSD root mean square of successive
differences, SpO2 pulse arterial oxygen saturation, TINN triangular interpolation NN,
VLF very low frequency, LF low frequency, HF high frequency. *P< 0.05
Table 1 Baseline characteristics of patients in the study
Characteristics All patients MACE No MACE P value
(n = 763) (n = 254) (n = 509)
Age in years, μ (σ) 60.49 (13.33) 61.75 (11.86) 59.86 (13.97) 0.001
Men 496 (64.9) 185 (72.8) 310 (60.9) 0.001
Race 0.647
Chinese 489 (64.1) 168 (66.1) 321 (63.1)
Malay 144 (18.9) 47 (18.5) 97 (19.1)
Indian 106 (13.9) 30 (11.8) 76 (14.9)
Other 24 (3.1) 9 (3.5) 15 (2.9)
Medical history
IHD 336 (44.0) 115 (45.3) 221 (43.4) 0.643
DM 275 (36.0) 113 (44.5) 162 (31.8) 0.001
Hypertension 492 (64.5) 173 (68.1) 319 (62.7) 0.149
Hyperlipidemia 456 (59.8) 148 (58.3) 308 (60.5) 0.584
Previous stroke 60 (7.9) 19 (7.5) 41 (8.1) 0.887
Cancer 32 (4.2) 8 (3.1) 24 (4.7) 0.345
Respiratory disease 31 (4.1) 4 (1.6) 27 (5.3) 0.012
Renal disease 96 (12.6) 34 (13.4) 62 (12.2) 0.644
CHF 39 (5.1) 10 (3.9) 29 (5.7) 0.383
Previous PCI 175 (22.9) 64 (25.2) 111 (21.8) 0.315
Previous CABG 70 (9.2) 25 (9.8) 45 (8.8) 0.690
Previous MI 114 (14.9) 41 (16.1) 73 (14.3) 0.519
Disposition from ED <0.001
Admission to GW 354 (46.4) 96 (37.8) 258 (50.7)
Admission to ICW 176 (23.1) 141 (55.5) 35 (6.9)
No admission 233 (30.5) 17 (6.7) 216 (42.4)
Data are number (%) unless otherwise specified. Patients may have had more
than one medical history and more than one disposition from the Emergency
Department (ED). P values <0.05 were considered statistically significant. MACE
major adverse cardiac event, SD standard deviation, IQR interquartile range,
IHD ischemic heart disease, DM diabetes mellitus, CHF congestive heart failure,
PCI percutaneous coronary intervention, CABG coronary artery bypass graft, MI
myocardial infarct, GW general ward, ICW intensive care ward
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Ten of the original 19 candidate variables remained in
the model after backwards variable elimination in the mul-
tivariable model. These were age, gender, heart rate, ST
elevation, ST depression, Q wave, QT prolongation, aver-
age R-to-R interval (AVRR), Triangular interpolation NN
(TINN), and high frequency (HF) (Table 4). The Hosmer-
Lemeshow test indicated satisfactory fit (p = 0.282). Out of
the ten predictors ST depression and ST elevation were
the strongest with odds ratios of 10.83 (95 % CI 5.49,
21.36) and 8.48 (95 % CI 4.27, 16.85), respectively.
The final set of criteria for the SEDRSM is shown in
Table 5. The unstandardized coefficients were normalized
by dividing the total set by 0.277, which was the smallest
common multiplicative factor. The normalized unstan-
dardized coefficients were subsequently rounded off to the
nearest integer. The SEDRSM has a range of 0 to 37.
The SEDRSM performed with an AUROC (or C statis-
tic) of 0.780 (95 % CI 0.743, 0.817), compared to an
AUROC of 0.653 (95 % CI 0.611, 0.695) for the TIMI
(UA/NSTEMI) score in the prediction of 30-day MACE.
The SEDRSM performed significantly better than the
TIMI score (p < 0.001). The ROC curves for the SEDRSM
and the TIMI score are shown in Fig. 1.
Figure 2 shows the SEDRSM score in relation to the
rate of MACE. With an increase of the score con-
structed in the SEDRSM there is a proportionate in-
crease in patients experiencing MACE. For example,
71.0 % of patients with the risk score of 15 or 16 have
30-day MACE. In Fig. 3, we did a further investigation
on the performance of the SEDRSM where the distribu-
tions of the risk scores are illustrated by outcome cat-
egories, that is, with and without 30-day MACE. The
gray bars indicate the score distributions for patients




P value Adjusted OR
(95 % CI)
Gender (male vs female) 0.773 <0.01 2.17 (1.45, 3.23)
Age, years (≥60 vs <60) 0.323 0.090 1.38 (0.95, 2.00)
Heart rate, beat/min 0.066
≥115 0 - 1.00
≤55 1.510 0.038 4.52 (1.08, 18.89)
56–114 0.716 0.243 2.05 (0.62, 6.80)
ST elevation (yes vs no) 2.138 <0.001 8.48 (4.27, 16.85)
ST depression (yes vs no) 2.382 <0.001 10.83 (5.49, 21.36)
Q wave (yes vs no) 1.076 0.004 2.93 (1.41, 6.11)
QT prolongation
(yes vs no)
0.372 0.054 1.45 (0.99, 2.12)
AVRR (<0.77 vs ≥0.77) 0.415 0.034 1.52 (1.03, 2.22)
TINN 0.006
0.11–0.17 0 - 1.00
<0.11 0.712 0.002 2.04 (1.30, 3.20)
>0.17 0.277 0.279 1.32 (0.80, 2.18)
HF power (<0.07 vs ≥0.07) 0.531 0.007 1.70 (1.16, 2.50)
MACE major adverse cardiac events, OR odds ratio, CI confidence interval, ED
emergency department, AVRR average RR, TINN triangular index NN, HF
high frequency
Table 5 Normalization of unstandardized coefficients and final
corresponding SEDRSM scores
Model criteria β Coefficients Final score
Gender, male 0.773 2.789 3
Age in years, ≥60 0.323 1.165 1
Heart rate, beat/min
≥115 0 0 0
≤55 1.510 5.448 5
56–114 0.716 2.582 3
ST elevation, yes 2.138 7.715 8
ST depression, yes 2.382 8.597 9
Q wave, yes 1.076 3.883 4
QT prolongation, yes 0.372 1.341 1
AVRR <0.77 0.415 1.498 1
TINN
0.11–0.17 0 0 0
<0.11 0.712 2.571 3
>0.17 0.277 1.000 1
HF power <0.07 0.531 1.916 2
Risk score ranges from 0 to 37. SEDRSM Singapore emergency department risk
stratification model, AVRR average RR, TINN triangular index NN, HF
high frequency
False positive rate (1-Specificity)

























Fig. 1 Receiver operating characteristic curves for the thrombolysis
in myocardial infarct (TIMI) score and Singapore Emergency
Department risk stratification model (SEDRSM) score
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with MACE in terms of percentage of total number of pa-
tients with MACE falling in each bin of the SEDRSM
score. The dotted bars indicate the score distributions for
patients without MACE. As seen from Fig. 3, the percent-
age of patients without MACE decreases generally from
32.3 % to 1.8 % as the risk stratification score increases,
whereas the percentage of patients with MACE fluctuates
in a range from 3.5 % to 27.6 %. Due to small numbers of
extreme scores we combined scores 0–6 and 17–37, and
paired the remaining numbers for illustration.
Table 6 contains the discriminatory values of the
SEDRSM and the TIMI score. The SEDRSM had better
sensitivity of 0.709 (95 % CI 0.653, 0.765) and specificity
of 0.674 (95 % CI 0.633, 0.715). The SEDRSM also had a
higher positive predictive value of 0.520 (95 % CI 0.468,
0.573) and a negative predictive value of 0.823 (95 % CI
0.786, 0.859).
Discussion
In this study we constructed a risk stratification model
(the SEDRSM) incorporating vital signs, demographic
data, ECG variables, and HRV parameters for the predic-
tion of 30-day MACE in patients presenting to the ED
with chest pain. In validation in the same cohort, the
SEDRSM significantly outperformed the TIMI score in
terms of AUROC (0.780 versus 0.653, p < 0.001). Add-
itionally, the SEDRSM performs better than the TIMI
score in terms of sensitivity, specificity, positive predict-
ive value, and negative predictive value.
Vital signs and 12-lead ECG variables are well-established
and frequently employed during clinical risk prediction on
the ED [11, 32]. In contrast, many studies have reported
the clinical and prognostic value of HRV parameters in
the evaluation of patients with possible cardiovascular
pathological conditions, but they have yet to be clinically
applied [33]. This study demonstrates that HRV parame-
ters can be successfully implemented in cardiovascular
risk stratification on the ED, even amidst other established
prognosticators. The TIMI score has been used as a
benchmark due to its popularity and accuracy in predict-
ing 30-day MACE in patients presenting to the ED with
chest pain [31]. We used short-term (6-minute) record-
ings of 12-lead ECG as it has practical advantages in the
time-scarce ED setting. Long-term (24-h) HRV analysis is
prone to data analysis difficulties (e.g., failure to detect




























































Fig. 3 The distribution of the Singapore Emergency Department risk stratification model (SEDRSM) score in patients with and without major
adverse cardiac events (MACE)
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Recent evidence demonstrated a comparable predictive
value for short-term vs long-term HRV analysis [34, 35].
The role of HRV in cardiovascular risk prediction has
been examined previously but we cannot make direct
comparisons with our study due to fundamental differ-
ences in methodology (i.e., no inclusion of 12-lead ECG
variables) and a low yield of patients meeting the primary
endpoints in previous reports [26].
Calculating HRV requires only ECG monitoring and
standard analysis software [36, 37]. The SEDRSM had an
AUROC of 0.780 versus an AUROC of 0.653 for the
TIMI score. Risk stratification models are considered
reasonable when the AUROC (or C statistic) is higher
than 0.7 and strong when it exceeds 0.8 [38]. Our find-
ings reaffirm the potential role of HRV amidst clinical
cardiovascular predictors such as 12-lead ECG variables,
and demonstrate a good performance compared to a
widely used cardiovascular ED risk prediction model;
however, there are still many opportunities for
enhancement.
Our results show that three HRV parameters are sig-
nificant predictors in a multivariable prediction model.
Additionally, four 12-lead ECG variables, and two demo-
graphic variables were strong significant predictors in
the multivariable model. Only one vital sign, heart rate,
was incorporated as a criterion into the model. The
heart rate can also be obtained through processing of
the 12-lead ECG. This tool would allow wider diffusion
of HRV parameters into clinical use as it enables HRV
parameter interpretation by the physician, which is
nearly impossible by manual methods. The SEDRSM al-
lows early clinical anticipation of MACE on the ED, and
thus facilitates early intervention.
HRV is a highly complex nonlinear phenomenon; even
though time-domain and frequency-domain HRV pa-
rameters are most frequently employed (designated as
the “classical analysis”) they are not fully representative
due to their linear and stationary nature. Evidence sug-
gests that nonlinear HRV parameters are much more suit-
able for the assessment and prognosis of cardiovascular
risk than the “classical analysis” [39]. However, more high-
quality longitudinal studies are required to establish the
applicability of nonlinear HRV parameters [13].
Fragmented QRS complex is an easily obtainable ECG
index that might further enhance cardiovascular risk
prediction models [40]. Signal averaged ECG analysis
has been demonstrated to have a high negative predict-
ive value [41], and could be employed simultaneously
with HRV processing. Microvolt T-wave alternans, a
measure of repolarization dispersion, has been employed
in the prediction of cardiac death and may add value to
HRV and signal averaged ECG (SAECG) analysis [42].
Last, the occurrence of specific early repolarization mor-
phological features that are frequently difficult to distin-
guish from true ST elevation, have recently been
associated with increased risk of unexpected death.
These patterns are considered particularly useful to re-
fine risk stratification and identify a high-risk subset of
patients; future research could explore the value of in-
corporating certain repolarization morphological fea-
tures into risk prediction using the HRV and 12-lead
ECG analysis [43, 44].
Limitations
In our study we have compared the performance of the
SEDRSM and the TIMI score for the prediction of 30-
day MACE in patients presenting to the ED with chest
pain. The SEDRSM score was only evaluated in our local
population, whereas the TIMI score has been popular
and widely validated, despite the fact that it was de-
signed for a slightly different specification [4]. Though
there is now evidence of its usefulness in this setting
[31], the usefulness of some of the criteria in the TIMI
score is questionable in the ED. For example, the TIMI
score requires knowledge of results of prior cardiac
catheterization, which might not be available. Newer risk
stratification scores have been developed that are specif-
ically calibrated towards patients presenting to the ED
with chest pain. For example, the history, ECG, age, risk
factors (HEART) score [45] and the Emergency Depart-
ment assessment of chest pain score (EDACS) score [46]
could serve as better benchmarks due to their applicabil-
ity to, and specific design for, an ED setting in which the
risk of 30-day MACE needs to be assessed [47].
Our study evaluates HRV as a quantitative measure of
a supposed quantitative primary endpoint, MACE. How-
ever, MACE includes revascularization (either through
PCI or CABG) as a category, which is not necessarily a
purely quantitative endpoint. Patient choice, i.e., the de-
cision by patients to reject revascularization at their own
risk, is a qualitative phenomenon. The revascularization
endpoint therefore interferes with the computation of
quantitative linear relationships between predictor and
endpoint. In our study we have not corrected for, or
Table 6 Discriminatory values for the SEDRSM and TIMI scores
SEDRSM TIMI
AUROC (95 % CI) 0.780 (0.743, 0.817) 0.653 (0.611, 0.696)
Cutoff score 9 2
Sensitivity (95 % CI) 0.709 (0.653, 0.765) 0.618 (0.558, 0.678)
Specificity (95 % CI) 0.674 (0.633, 0.715) 0.572 (0.529, 0.615)
PPV (95 % CI) 0.520 (0.468, 0.573) 0.419 (0.369, 0.469)
NPV (95 % CI) 0.823 (0.786, 0.859) 0.750 (0.707, 0.793)
The Singapore Emergency Department risk stratification model (SEDRSM) has a
range of 0 to 37; the thrombolysis in myocardial infarct (TIMI) score has a
range of 0 to 7. AUROC area under the receiver operating characteristic, CI
confidence interval, PPV positive predictive value, NPV negative
predictive value
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quantified the number of patients rejecting medical diag-
nostics or therapy at any point after presentation to the
ED. A modification of endpoint or exclusion of these pa-
tients would likely facilitate a more accurate linear rela-
tionship between predictor and endpoint.
In addition to the above limitations, we note that HRV
parameters can not be manually calculated or interpreted.
In this study, we used our in-house software to derive
HRV measurements. We are currently developing a port-
able hardware device to integrate data acquisition and
analysis. We believe that such a device will help clinicians
quickly identify patients at high risk of developing MACE.
Conclusions
In our single-center, single-cohort study of patients pre-
senting to the ED with chest pain, our risk stratification
model (the SEDRSM) outperformed the TIMI score for
the prediction of MACE, a composite endpoint of MI, re-
vascularization, and death (AUROC of 0.780 versus 0.653
respectively). The SEDRSM incorporated the following
criteria: age, gender, heart rate, three HRV parameters,
and four 12-lead ECG variables. The SEDRSM provides
useful information for making decisions about the place-
ment of ED patients with chest pain under observation,
and in determining the therapeutic strategy. The SEDRSM
contains eight criteria that can be acquired by processing
electrocardiographic data, allowing for a 12-lead ECG-based
risk prediction device, setting aside only the manual input
of demographic criteria. A risk stratification device could
employ machine learning techniques that reduce informa-
tion loss occurring during the construction of multivariable
linear association models. There are several other ECG-
based variables that can be valuable additions to our risk
stratification score; these include nonlinear HRV parameters
and novel depolarization or repolarization ECG variables.
Our study demonstrates the potency and suitability of the
SEDRSM for cardiovascular risk prediction in the ED, but
also warrants evaluation and possibly resolution of existing
limitations before it can be implemented in clinical practice.
Key messages
 The Singapore General Hospital (SGH) Emergency
Department risk stratification model (SEDRSM) was
proposed for patients with chest pain
 The SEDRSM outperformed the TIMI score in
predicting 30-day major adverse cardiac events
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